Pascolizumab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 458269502

| image =

| type = mab

| mab_type = mab

| source = zu/o

| target = IL-4

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 331243-22-2

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| IUPHAR_ligand = 7786

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = N1IOA09R6A

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| chemical_formula =

| molecular_weight =

}}

Pascolizumab is a humanized monoclonal antibody for the treatment of asthma.{{cite journal | vauthors = Hart TK, Blackburn MN, Brigham-Burke M, Dede K, Al-Mahdi N, Zia-Amirhosseini P, Cook RM | title = Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma | journal = Clinical and Experimental Immunology | volume = 130 | issue = 1 | pages = 93–100 | date = October 2002 | pmid = 12296858 | pmc = 1906490 | doi = 10.1046/j.1365-2249.2002.01973.x }} A Phase II clinical trial in patients with symptomatic glucocorticoid naive asthma was conducted in 2001/2002.{{ClinicalTrialsGov|NCT00024544|Pilot Study in Patients With Symptomatic Steroid-Naive Asthma}} Development was discontinued as it showed little benefit.{{cite journal | vauthors = Bice JB, Leechawengwongs E, Montanaro A| title = Biologic targeted therapy in allergic asthma| journal = Annals of Allergy, Asthma & Immunology| volume = 112 | issue = 2 | page = 108 - 115| year = 2014 | doi = 10.1016/j.anai.2013.12.013}}